MMS Holdings exists to solve one of the most critical bottlenecks in modern medicine: getting life-saving treatments from lab to patient faster and more reliably. Every year, pharmaceutical and biotech companies lose valuable time navigating the increasingly complex landscape of clinical trial data and regulatory submissions. MMS, a global data-focused Contract Research Organization (CRO), tackles this challenge head-on by combining regulatory expertise with innovative technology solutions that streamline the entire drug development process.
Founded in 2006 by Dr. Uma Sharma, MMS has grown from a one-person consultancy into a trusted partner with over 950 colleagues across four continents, maintaining an industry-leading 97 percent customer satisfaction rating. The company's mission is grounded in real impact: delivering high-quality service and technology solutions rooted in strong science and decades of regulatory experience that help clients develop and market life-changing therapies worldwide. Through their proprietary platforms including Datacise®, Automatiqc®, PVantage®, and KerusCloud®, MMS enables sponsors to navigate the difficult path of regulatory compliance with confidence.
